NCT03405090View on ClinicalTrials.gov

Differential Mechanisms of Dyspnea Relief in Advanced COPD: Opiates vs. Bronchodilators

PHASE4CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

September 20, 2017

Primary Completion Date

March 21, 2022

Study Completion Date

March 31, 2023

Conditions
Chronic Obstructive Pulmonary Disease
Interventions
DRUG

Fentanyl Citrate

100 mcg fentanyl citrate will be inhaled via nebulizer

DRUG

Combivent

0.5 mg ipratropium bromide + 2.5 mg salbutamol will be inhaled via nebulizer

Trial Locations (1)

K7L 2V7

Respiratory Investigation Unit, Kingston

All Listed Sponsors
collaborator

Ontario Lung Association

OTHER

collaborator

Queen's University

OTHER

lead

Dr. Denis O'Donnell

OTHER

NCT03405090 - Differential Mechanisms of Dyspnea Relief in Advanced COPD: Opiates vs. Bronchodilators | Biotech Hunter | Biotech Hunter